PepsiCo, Inc. (PEP) Stock Price Today
Aura AI Summary
Key Stats
- $199.55BMarket Cap
- 10,593,689Volume
- Consumer StaplesSector
- $170.4452W High
- $123.6452W Low
- 108 DaysTypical Hold Time
- $240.26BEnterprise Value
- 4.04%Div Yield
- 51% Sell | 49% BuyTrading Activity
Track PepsiCo, Inc. (PEP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, PepsiCo, Inc. has traded between a low of $123.64 and a high of $170.44, highlighting its annual price range. Buy and sell PepsiCo, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Most Recent News
BNL aims for pre-tax RONE above 20% by 2030 through strategic growth and digital transformation.
BNL, part of BNP Paribas, is accelerating its growth strategy with a focus on high-value client services in Corporate Banking, Private Banking, and Wealth Management. It plans to enhance profitability by investing in digitalization, AI, and employee ...

BNL aims for over 20% pre-tax RONE by 2030 through strategic repositioning and investment in high-value activities.
BNL, part of BNP Paribas, is accelerating its growth with a strategic focus on high-value client activities like Corporate Banking, Private Banking, and Wealth Management. It plans to improve operational efficiency through digitalization and AI, inve...

Safety committee approves dose increase to 15 mg/kg in Entrada's Duchenne muscular dystrophy trial
Entrada Therapeutics announced that an independent safety committee recommended increasing the dose to 15 mg/kg for Cohort 3 in their Phase 1/2 ELEVATE-45-201 trial targeting Duchenne muscular dystrophy. This follows the completion of Cohort 2 at 10 ...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.